Abstract
Objective(s): Multiple sclerosis (MS) is a chronic demyelinating neurological disorder characterized by the loss of sensory and motor functions. In 2019, the estimated prevalence and incidence of MS in Kuwait per 100,000 people was 104.9 and 5.39, respectively. Cladribine tablets are the first oral short-course treatment approved for highly active relapsing multiple sclerosis across various geographies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
